Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and Zimberelimab Neoadjuvant Therapy for HNSCC
NCT06107114Phase 2Unknown
- Start
- Dec 2023
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zimberelimab in head and neck squamous cell carcinoma (HNSCC). Primary endpoint: Objective Response Rate at 9 weeks. Status: unknown.
02
Drugs
zimberelimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06107114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06107114.